Personalizing medicine for metastatic colorectal cancer: Current developments

Andrea Marin Marques, Alice Turner, Ramon Andrade de Mello

Metastatic colorectal cancer (mCRC) is still one of the tumor types with the highest incidence and mortality. In 2012, colorectal cancer was the second most prevalent cancer among males (9%) and the third among females (8%). In this disease, early diagnosis is important to improve treatment outcomes. However, at the time of diagnosis, about one quarter of patients already have metastases, and overall survival of these patients at 5-years survival is very low. Because of these poor statistics, the development of new drugs against specific targets, including the pathway of angiogenesis, has witnessed a remarkable increase. So, targets therapies through epidermal growth factor and its receptor and also KRAS pathways modulation acquired a main role whether in association with standard chemotherapy and radiotherapy. With the current knowledge in the field of molecular biology, including genetic mutations and polymorphisms, we know better why patients respond so differently to the same treatments. So, in the future we can develop increasingly personalized treatments to the patient and not the disease. This review aims to summarize some molecular pathways and their relation to tumor growth, as well as novel targeted developing drugs and recently approved for mCRC.

INTRODUCTION

Colorectal cancer (CRC) has high incidence and mortality worldwide. In 2012, CRC was the second most prevalent cancer type among males (9%) and the third among females (8%). Approximately 15%-25% of patients with CRC present with synchronous liver metastases, and
Angiogenesis is a complex process mediated by a number of intersecting pathways, including VEGF, angiopoietins, notch, and integrins (Figure 1). In normal tissues, there is a balance between proangiogenic and antiangiogenic factors[8]. The VEGF family comprises VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PIGF), 3 receptors [VEGF receptor (VEGFR)-1 (FLT-1), VEGFR-2 (FLK-1/KDR), and VEGFR-3 (FLT-4)], and 2 co-receptors [neuropilin (NRP)-1 and NRP-2]. VEGF-A binding to VEGF receptor (VEGFR)-2 is believed to be the key signaling pathway mediating angiogenesis[10], by the increase of endothelial proliferation and survival it promotes endothelial cell migration, increases vascular permeability, and alters gene expression. Tyrosine kinases are receptors for VEGF ligands and they are found primarily on vascular endothelial cells[11].

Tumor angiogenesis has peculiarities relating to the same process in healthy tissue. The endothelial layer is irregular and contains spaces that contribute to the extravasation of particles as large as 2 μm from tumor vessels[12], proliferating tumor cells cause compression of vessels[13], and interstitial pressure is increased. This causes an inadequate delivery of therapeutic agents such as monoclonal antibodies[14]. The ability of tumor vessels to supply oxygen and remove waste products is thus compromised, resulting in hypoxia and acidosis in the tumor microenvironment. This further lowers the effectiveness of anti-tumor treatments such as radiation therapy and chemotherapy[15].

CHEMOTHERAPY FOR ADVANCED OR mCRC

Relative to the standard chemotherapy for advanced or mCRC; the guidelines advocate the use of the following schemes in initial therapy: fluorouracil, leucovorin, and oxaliplatin-based chemotherapy (FOLFOX), fluorouracil, leucovorin, and irinotecan-based chemotherapy (FOLFIRI)[16] capcitabine plus oxaliplatin (CapOx or XELOX)[17] and fluorouracil, leucovorin, oxaliplatin and irinotecan-based chemotherapy (FOLFOXIRI)[18]. These drugs have been used since the 90's for providing an improvement in the overall survival (OS) for metastatic patients[19].

In chemotherapy for advanced and mCRC, the addition of a biologic agent is also advocated. The biologics agents for CRC include an anti-VEGF (bevacizumab)[20] or an anti-EGFR (cetuximab or panitumumab) for KRAS wild-type (WT) gene patients. They are recommended or listed as an option in combination with some of the regimens above. The OS was not found to be associated with the order in which these drugs were received. After the first progression of the disease, the therapeutic regimen used should be changed, but some studies have demonstrated the benefit of continuing angiogenic suppression after first-progression following bevacizumab-containing cytotoxic regimen[21] though no benefit was observed with the use of bevacizumab in the adjuvant setting.

ANTI-EGFR THERAPY

In mCRC, the anti-EGFR therapy that can be used is cetuximab and panitumumab. These are monoclonal antibodies that can be administered as monotherapy for patients with the KRAS wild type, or in association with standard chemotherapy[22]. Cetuximab was approved with 5-FU, leucovorin and irinotecan (FOLFIRI) for first-line therapy[23], on the other hand panitumumab was approved for use as monotherapy.
ANTI-VEGF THERAPY

In the class of Anti-VEGF therapy, bevacizumab and aflibercept are currently interesting options. Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of VEGF by preventing its binding to VEGFR-1 and VEGFR-2 on the surface of endothelial cells. The result is inhibition of endothelial cell proliferation and new blood vessel formation[24-26]. Aflibercept (VEGF Trap, known in the United States as ziv-aflibercept), is a recombinant fusion protein with receptor components of VEGFR-1 and VEGFR-2 that binds multiple ligands in the angiogenesis network (VEGF-A, VEGF-B, and PlGF). It was demonstrated that this targeted therapy improved the survival of mCRC patients as second-line treatment in combination with the FOLFIRI regimen in patients who had disease progression during first-line oxaliplatin-based chemotherapy[27,28]. Despite the demonstrated effectiveness in progression-free-survival (PFS) and OS with the use of bevacizumab in combination with common cytotoxic chemotherapies[29], there are some mechanisms of resistance to VEGF targeting[30]. In this framework, some hypotheses have been raised, such as the VEGF axis related resistance, the role of non-VEGF modulators of angiogenesis in resistance, and the significance of the stroma in the response to angiogenesis targeting[31].

CLINICAL DATA

At the current time, there are 8 new anti-angiogenic agents in trials and a new molecule approved by Food and Drug Administration (FDA) and European Medicine Agency (EMA)[32]. We will summarize below some important aspects regarding the main drugs in this field (Table 1).

Aflibercept

First, aflibercept, a fully humanized recombinant fusion protein that is composed of domain 2 of VEGFR-1 and domain 3 of VEGFR-2 with the Fc fragment of IgG1[33] as mentioned above. The phase III VELOUR trial determined that patients receiving aflibercept with irinotecan/5-FU as second line chemotherapy for mCRC experienced increased time of outcomes: median PFS for the aflibercept plus FOLFIRI arm was 6.90 mo vs 4.67 mo for the placebo-plus-FOLFIRI arm; and median OS for the aflibercept-plus-FOLFIRI arm was 13.50 mo vs 12.06 mo for the placebo plus FOLFIRI arm. In this study, 1226 patients were randomized to receive FOLFIRI plus placebo or aflibercept. However, toxicity (grade 3 or 4 of adverse events) were more common with the addition of aflibercept (n = 614) than in placebo (n = 612); also, nearly 1/3 of these patients had previously been treated with bevacizumab[34]. The most common adverse events were: fatigue (63.8%), nausea (36.2%) and vomiting (27.7%), while the most common toxicities included dysphonia (46.8%), hypertension (38.3%) and proteinuria (10.6%)[35].

Sunitinib

Sunitinib is a small-molecule inhibitor of the VEGF pathway. It is a multi-targeted receptor tyrosine kinase inhibitor (TKI), with both direct anti-proliferative effects and anti-angiogenic properties, targeting the VEGFR-2 as well as PDGFR-b, c-Kit and Ret[36]. However a recent study showed that sunitinib plus FOLFIRI was not superior to FOLFIRI alone and has a poorer safety profile in treatment of mCRC patients[37].

Vatalanib

Another biological agent is vatalanib, a TKI that blocks the activity of VEGF-1, VEGF-2 and VEGF-3. It also inhibits other class III kinases, such as the platelet-derived growth factor (PDGF) receptor beta tyrosine kinase, c-Kit, and c-Fms, but at higher concentrations[38]. Phase I / II studies have shown good results, but the data from a phase III study, CONFIRM-1, showed that the addition of vatalanib to FOLFOX-4 did not improve PFS. This was compared with FOLFOX-4 alone in patients with mCRC in first line treatment[39]. Nevertheless, the CONFIRM-2[40], which evaluated the same therapy as second line, showed that in patients with high levels of lactate dehydrogenase, vatalanib could be useful[41].

Semaxanib

Semaxanib is an inhibitor of VEGFR-1 and 2 tyrosine kinases that was shown to inhibit VEGF-dependent angiogenesis of human endothelial cells without inhibiting the growth of a variety of tumor cells in vitro[42]. However, the results in phase III trials did not show any improvement in clinical outcome with semaxanib in combination with irinotecan vs fluorouracil irinotecan alone, as therapy for advanced CRC patients that had failed at least one prior treatment[43]. As well as this, severe toxicity was observed.

Regorafenib

Regorafenib is a TKI against various pro-angiogenic and pro-proliferation targets[44]. It is the first anti-angiogenic molecule with survival benefits in mCRC which has progressed after all standard therapies[45]. In the CORRECT phase III trial, it was randomized for 753 patients to initiate treatment (regorafenib n = 500; placebo n = 253; population for safety analyses). Median OS, the primary end-point, was 6.4 mo in the regorafenib group vs 5.0 mo in the placebo group (HR = 0.77; 95%CI: 0.64-0.94; one-sided P = 0.0052). Treatment-related adverse events occurred in 465 (93%) patients assigned regorafenib and in 154 (61%) of those assigned placebo. The most common adverse events of grade three or higher related to regorafenib were hand-foot skin reaction (83 patients, 17%), fatigue (48.10%), diarrhea (36.7%), hypertension (36.7%), and rash or desquamation (29.6%). These results were interesting, particularly, for the patients with KRAS mutant mCRC.
Table 1  Summary of the main clinical trials regarding anti-angiogenic therapies

| Drugs       | Ref.  | Trial                     | Summary of the study                                                                 | Results (PFS; OS)                                                                                   | Toxicity (grade 3 or 4 adverse events) |
|-------------|-------|---------------------------|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|---------------------------------------|
| Aflibercept | [33]  | VELOUR trial             | aflibercept with irinotecan/5-FU/LV as second line chemotherapy for mCRC              | Median PFS for the aflibercept plus FOLFIRI arm was 6.90 mo vs 4.67 mo for the placebo-plus-FOLFIRI arm | Grade 3 or 4 adverse events were more common with the addition of aflibercept (n = 614) or placebo (n = 612), nearly 1/3 of these patients had previously been treated with bevacizumab |
|             |       |                           |                                                                                      | Median OS for the aflibercept-plus-FOLFIRI arm was 13.50 mo vs 12.06 mo for the placebo plus FOLFIRI arm |                                                                                                      |
| Sunitinib   | [36]  | Carrat et al[46]         | Double-blinded, phase II study participants were randomly assigned to sunitinib plus FOLFIRI or placebo plus FOLFIRI | Median PFS for the sunitinib arm was 7.8 mo (95%CI: 7.1-8.4 mo) vs 8.4 mo (95%CI: 7.6-9.2 mo) for the placebo arm | Diarrhea, stomatitis/oral syndromes, fatigue, hand-foot syndrome, neutropenia, thrombocytopenia, anemia, and febrile neutropenia |
| Vatalanib   | [38-40]| CON-FIRM-1/CONFIRM-2     | These are multinational, randomized, double-blinded, phase III studies. Patients were randomly assigned to receive vatalanib plus FOLFOS or placebo plus FOLFOX in 1º or 2º line respectively for CONFIRM-I or CONFIRM-2 | Vatalanib and placebo, respectively, presented median OS was 13.1 and 11.9 mo (HR = 1.00; 95%CI: 0.87-1.16; P = 0.957). Median PFS was with placebo (5.6 and 4.2 mo, respectively; HR = 0.83; 95%CI: 0.71-0.96; P = 0.013). An exploratory, post hoc analysis demonstrated improved PFS in patients with high LDH, regardless of WHO PS (HR = 0.63; 95%CI: 0.48-0.83; P < 0.001) | The incidence of grade 3/4 neutropenia was similar for both groups; however, a higher percentage of patients in the vatalanib group experienced grade 3/4 hypertension, diarrhoea, fatigue, nausea, vomiting, dizziness, confused state, deep vein thrombosis, and pulmonary embolism |
| Semaxanib   | [42]  |                           | Study conducted with the objective of determining the maximum tolerated dose and dose-limiting toxicities in combination with weekly irinotecan in patients with advanced CRC who had failed at least one prior treatment | NA                                                                                                   | There were no drug-related Grade 4 toxicities. There was one episode of Grade 3 headache and one episode of Grade 3 vomiting |
| Regorafenib | [44]  | CORRECT trial            | Patients with mCRC and progression during or within 3 mo after the last standard therapy were randomised to receive best supportive care plus oral regorafenib 160 mg or placebo once daily, for the first 3 wk of each 4 wk cycle | Median OS was 6.4 mo in the regorafenib group vs 5.0 mo in the placebo group (HR = 0.77; 95%CI: 0.64-0.94; one-sided P = 0.0052) | The grade 3 or higher of adverse effects related to regorafenib were hand-foot skin reaction (83 patients, 17%), fatigue (48, 10%), diarrhoea (36, 7%), hypertension (36, 7%), and rash or desquamation (29, 6%) |
| Brivanib    | [47]  | Siu et al[47]            | Patients previously treated were assigned 1:1 to receive cetuximab 400 mg/m intravenous loading dose followed by weekly maintenance of 250 mg/m plus either brivanib 800 mg orally daily (arm A) or placebo (arm B) | Median OS in the intent-to-treat population was 8.8 mo in arm A and 8.1 mo in arm B (HR = 0.88; 95%CI: 0.74-1.03; P = 0.12). Median PFS was 5.0 mo in arm A and 3.4 mo in arm B (HR = 0.72; 95%CI: 0.62-0.84; P < 0.001) | Grade ≥ 3 adverse events was 78% in arm A and 53% in arm B |
| Cediranib   | [48]  | HORIZON III              | Patients randomly assigned 1:1:1 received FOLFOLX6 with cediranib or bevacizumab   | There are not significant differences in PFS (HR = 1.10; 95%CI: 0.97-1.25; P = 0.119), OS (HR = 0.95; 95%CI: 0.82-1.10; P = 0.541) and overall response rate (46.3% vs 47.3%) | Cediranib arm adverse events included diarrhea, neutropenia, and hypertension |

PFS: Progression free survival; OS: Overall survival; HR: Hazard ratio; 5-FU: 5-fluourouracil; LV: Leucovorin; FOLFIRI: 5-FU, LV and irinotecan; FOLFOX: 5-FU, LV and oxaliplatin; mCRC: Metastatic colorectal cancer; NA: Not available.

**Brivanib**  
Another molecule being studied is brivanib, a TKI that specifically inhibits the VEGFR-2 and FGFR-1 signaling[45]. Some studies have been shown that brivanib can be used to restore the antiangiogenic activity in bevacizumab-resistant patients[46]. A recent phase III trial that compared the use of brivanib and cetuximab with or without chemotherapy, demonstrated that despite positive effects on PFS and objective response, cetuximab plus brivanib increased toxicity and did not significantly improve OS in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal cancer[47]. Taking this in account, more data are needed to clarify this issue.

**Cediranib**  
Cediranib, a VEGFR tyrosine kinase inhibitor (VEGFR TKI), was tested in the HORIZON III trial[48] in which cediranib plus FOLFOX6 was compared with bevacizumab plus FOLFOX6 in patients with untreated mCRC. The results did not show significant differences in the...
use of cediranib or bevacizumab with respect to OS and PFS. Thus, this drug is not currently used in our clinical practice.

CONCLUSION

Nowadays, the new era of molecular cancer profiling has emerged in order to help clinicians in their decision making. Taking this into account, many targeted drugs are objects of extensive interest for the scientific community. In colorectal cancer, only bevacizumab, cetuximab, regorafenib and panitumumab have acquired sufficient evidence to be used in combination with standard chemotherapy to improve patient outcomes. However, the results are not strong enough for the national public systems to support their complete use in all countries. Pharmaco-economics studies are needed prior to approve those biological drugs towards the cancer care institutions. However, it is important for oncologists to be aware of patients cost and benefit in order to provide the best care for mCRC patients.

REFERENCES

1 Siegel R, D'Santis C, Virgo K, Steen K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachev M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-241 [PMID: 22700443 DOI: 10.3322/caac.21149]

2 Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, Ychou M, Rougier P. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212-2221 [PMID: 16904315 DOI: 10.1016/j.ejca.2006.04.012]

3 Muratore A, Zorzi D, Bouzari H, Amisano M, Massucco P, Sperti E, Capussotti L. Asymptomatic colorectal cancer with un-resectable liver metastases: immediate colorectal resection or up-front systemic chemotherapy? Ann Surg Oncol 2007; 14: 766-770 [PMID: 17103261 DOI: 10.1245/s10434-006-0916-4]

4 Midgley R, Kerr D. Conventional cytotoxic and novel therapeutic concepts in colorectal cancer. Expert Opin Investig Drugs 2001; 10: 1011-1019 [PMID: 11772231 DOI: 10.1517/13543784.10.6.1011]

5 Cercek A, Saltz L. Evolving treatment of advanced colorectal cancer. Curr Oncol Rep 2010; 12: 153-159 [PMID: 20425074 DOI: 10.1007/s11912-010-0096-1]

6 Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer. N Engl J Med 2004; 351: 337-345 [PMID: 15269133 DOI: 10.1056/NEJMoa030325]

7 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Grifing S, Holmgren E, Ferrara N, Fye G, Rogers B, Ross R, Kabbapnavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342 [PMID: 15175435 DOI: 10.1056/NEJMoa032691]

8 Laurent-Puig P, Cayre A, Manceu G, Buc E, Batch J, Lecomte T, Rougier P, Lievre A, Landi B,Boige V, Ducrue M, Ychou M, Biébé F, Bouché O, Reid J, Stone S, Peault-Llorca F. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS-mutant colorectal cancer. J Clin Oncol 2009; 27: 5924-5930 [PMID: 19884556 DOI: 10.1200/JCO.2008.21.6796]

9 Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62 [PMID: 15637262 DOI: 10.1126/science.1105430]

10 Sun W. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol 2012; 5: 63 [PMID: 23057939 DOI: 10.1186/1756-8722-5-63]

11 Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-4380 [PMID: 12409357 DOI: 10.1200/JCO.2010.10.088]

12 Choong HL, Pwee HS, Woo KT, Lim CH. Maintenance haemodialysis in Singapore. Singapore Med J 1991; 32: 133-138 [PMID: 1876882 DOI: 10.1016/S0002-9440(10)65006-7]

13 Padera TP, Stoll BR, Tooodman JB, Capen D, di Tomaso E, Jain RK. Pathology: cancer cells compress intratumour vessels. Nature 2004; 427: 695 [PMID: 14937470 DOI: 10.1038/427695a]

14 Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990; 50: 4478-4484 [PMID: 2569726]

15 Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 2010; 17: 206-225 [PMID: 20374484 DOI: 10.1111/j.1549-8719.2010.00029.x]

16 Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iverson T, Caanmichael J, Alaki M, Gruia G, Awad L, Rougier P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047 [PMID: 10744089 DOI: 10.1016/S0140-6736(00)02034-1]

17 Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinizer M, Yang TS, Rivera F, Couture P, Sirzén F, Saltz L. Randomized phase III study of cetapabine plus oxaplatin compared with fluorouracil/folinic acid plus oxaplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012 [PMID: 18410535 DOI: 10.1200/jco.2007.14.9898]

18 Falcone A, Ricci S, Brunetti I, Pfanner E, Allegri G, Barbosa C, Cirino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitelli S, Chiara S, Granetto C, Porcile G, Fioretto I, Orlandini C, Andreucetti M, Masi G. Phase III trial of infusional fluorouracil, leucovorin, oxaplatin, and irinototecan (FOLFIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676 [PMID: 17470860 DOI: 10.1200/jco.2006.09.0928]

19 Grotehly A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-1214 [PMID: 15051767 DOI: 10.1200/jco.2004.11.037]

20 Saif MW. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer? Anticancer Res 2013; 33: 2377-2380 [PMID: 23754988]

21 Bennouna J, Saxtre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, von Moos R, Vieitez JM, Bouché O, Borg C, Stefanis CC, Alonso-Orduña V, Stefán SC, de-Scarbrough S. Discontinued cediranib plus oxaplatin as third-line therapy in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37 [PMID: 23168366 DOI: 10.1016/S1470-2045(12)70477-1]

22 Haraldsdottir S, Bekai-Saab T. Integrating anti-EGFR therapies in metastatic colorectal cancer. J Gastrointest Oncol 2013; 4: 285-298 [PMID: 23997940]

23 Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien
Marques AM et al. Targeted therapies and mCRC

CR, Makhson A, D’Haens G, Pintet T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Teijpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009; 360: 1408-1417 [PMID: 19539720 DOI: 10.1056/NEJMoa0805019]

24 Jain RK, Duda DG, Clark JW, Loefller JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. *Nat Clin Pract Oncol* 2006; 3: 24-40 [PMID: 16407877]

25 Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. *Nat Rev Drug Discov* 2004; 3: 391-400 [PMID: 15136787]

26 Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of metastatic colorectal cancer. *Oncolist* 2007; 12: 356-361 [PMID: 17405901 DOI: 10.1634/theoncologist.12-3-356]

27 Tabernero J, Van Cutsem E, Lakomy R, Prausová J, Ruff P, van Hazel GA, Moiseyenko VM, Ferry DR, McKendrick JJ, Soussan-Lazard K, Chevalier S, Allegra CJ. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. *Eur J Cancer* 2014; 50: 320-331 [PMID: 24140268 DOI: 10.1016/j.ejca.2013.09.013]

28 Chung C, Pherwani N. Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer. *Am J Surg Pathol* 2013; 37: 1887-1896 [PMID: 24128964 DOI: 10.1097/PS.0b013e3182972a6c]

29 Menon RS, Rusinko MS, Allen PS. Proton relaxation studies of water compartmentalization in a model neurological system. *Magn Reson Med* 1992; 26: 264-274 [PMID: 1281258 DOI: 10.1002/mrm.1910280208]

30 Clarke JM, Hurwitz HI. Understanding and targeting resistance to anti-angiogenic therapies. *J Gastroint Oncol* 2013; 4: 253-263 [PMID: 23997938 DOI: 10.3978/j.issn.2078-6891.2013.036]

31 Clomborn KK, Berlin J, Chan E. Aflibercept. *Clin Cancer Res* 2013; 19: 1920-1925 [PMID: 23444216 DOI: 10.1158/1078-0432.ccr-12-2911]

32 Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. *Expert Opin Biol Ther* 2009; 9: 263-271 [PMID: 19256257 DOI: 10.1517/14712598062663697]

33 Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macanulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Telleria A, Castan R, Allegra C. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. *J Clin Oncol* 2012; 30: 3499-3506 [PMID: 22949147 DOI: 10.1200/jco.2012.42.8201]

34 Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Danly P, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierau-KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F. PTK787/ZK 22584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. *Cancer Res* 2000; 60: 2178-2189 [PMID: 10786652]

35 Abstracts of the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO). May 13-17, 2005. Orlando, Florida, USA. *J Clin Oncol* 2005; 23: 1-10875 [PMID: 15957209]

36 Van Cutsem E, Bajetta E, Valle J, Köhne CH, Hecht JR, Moore M, Germond C, Berg W, Chen BL, Jalava T, Lewbohl D, Meinhardt G, Laurent D, Lin E. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 22584 in patients with previously treated metastatic colorectal adenocarcinoma. *J Clin Oncol* 2011; 29: 2004-2010 [PMID: 21464401 DOI: 10.1200/jco.2010.29.5436]

37 Kohne C, Bajetta E, Lin E. Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 22584 (PTK/ZK) or placebo. *J Clin Oncol* 2007; 25 (Suppl 18S): 4033.

38 Hoff PM, Wolff RA, Bogaard K, Waldrum S, Abbruzzese JL. A Phase I study of escalating doses of the tyrosine kinase inhibitor sunitinib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma. *Ipn J Clin Oncol* 2006; 36: 100-103 [PMID: 16449240 DOI: 10.1093/jco/hjy229]

39 Kies M, Blumenschein GJ, Christensen O. Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC). *J Clin Oncol* 2010; 28 (15 Suppl): 7585.

40 Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humbert Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent D, Cihon F, Cupit L, Wagner A, Laurent D. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet* 2013; 381: 303-312 [PMID: 23177514 DOI: 10.1016/s0140-6736(12)61900-x]

41 Cai ZW, Zhang Y, Borzilieri RM, Qian L, Barbosa S, Wei D, Zheng X, Wu L, Fan J, Shi Z, Wautlet BS, Mortillo S, Jayesaelan R, Kukral DW, Kamath A, Marathe P, D’Arienzo C, Derbin G, Barrish JC, Rohl JA, Hunt JT, Lombardo LJ, Fargnoli J, Bühde RS. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolido[2,1-f,1,2,4]triazin-3-yl)pyran-2-yl)(2-hydroxypropanoato), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-542015). *J Med Chem* 2008; 51: 1976-1980 [PMID: 18288793 DOI: 10.1021/jm0713309]

42 Lieu C, Heymach J, Overman M, Tran H, Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. *Clin Cancer Res* 2011; 17: 6130-6139 [PMID: 21953501 DOI: 10.1158/1078-0432.ccr-11-0659]
Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer MB, Jefford M, Magoski NM, Haydon A, Walters I, Ringash J, Tu D, O’Callaghan CJ. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. J Clin Oncol 2013; 31:2477-2484 [PMID: 23690424 DOI: 10.1200/jco.2012.46.0543]

Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol 2012; 30:3588-3595 [PMID: 22965961 DOI: 10.1200/jco.2012.42.5355]

P- Reviewer: Cullen JJ, Perini MV, Sipos F
S- Editor: Qi Y
L- Editor: A
E- Editor: Liu XM
